- Conatus Pharmaceuticals (NASDAQ:CNAT) is up 40% premarket on robust volume in response to its announcement of a conference call on Thursday to discuss the results from three clinical trials. Investors clearly anticipate good news.
- Previously: Conatus to report results from three clinical trials on Thursday (Jan. 5)
Conatus up big premarket
Recommended For You
More Trending News
About HSTO Stock
Related Stocks
| Symbol | Last Price | % Chg |
|---|---|---|
| HSTO | - | - |
| Histogen Inc. | ||